#Camurus

Thiard News@F4F

@newsen.bsky.social

2 months ago

Camurus' Oclaiz™ NDA Resubmission Accepted by FDA: A Huge Leap for Acromegaly Treatment Camurus celebrates FDA's acceptance of their NDA resubmission for Oclaiz™, an innovative treatment for acromegaly, aiming for availability by June 2026.

Camurus' Oclaiz™ NDA Resubmission Accepted by FDA: A Huge Leap for Acromegaly Treatment #Sweden #FDA #Lund #Camurus #Oclaiz™

Thiard News@F4F

@newsen.bsky.social

2 months ago

Camurus Receives FDA Green Light for Oclaiz™ to Combat Acromegaly Camurus announces that the FDA has accepted its NDA resubmission for Oclaiz™, an innovative treatment for acromegaly, with a target decision date set for June 2026.

Camurus Receives FDA Green Light for Oclaiz™ to Combat Acromegaly #Sweden #Lund #Camurus #Acromegaly #Oclaiz™

Thiard News@F4F

@newsen.bsky.social

4 months ago

Camurus Announces Remarkable Results for Monthly Semaglutide CAM2056 in Phase 1b Study Camurus reports impressive topline findings from Phase 1b study on CAM2056, a monthly semaglutide formulation, showing significant weight loss and A1c reductions.

Camurus Announces Remarkable Results for Monthly Semaglutide CAM2056 in Phase 1b Study #Sweden #Lund #Semaglutide #Camurus #CAM2056

Thiard News@F4F

@newsen.bsky.social

4 months ago

Camurus Reports Remarkable Results for New Semaglutide Depot CAM2056 in Weight and Glycemic Control Camurus has unveiled promising findings from their Phase 1b study of CAM2056, a monthly semaglutide depot, revealing significant weight loss and A1c improvements.

Camurus Reports Remarkable Results for New Semaglutide Depot CAM2056 in Weight and Glycemic Control #Sweden #Lund #Semaglutide #Camurus #CAM2056

Thiard News@F4F

@newsen.bsky.social

6 months ago

Camurus Receives Green Light for Oczyesa® to Treat Acromegaly in the UK Camurus’ Oczyesa®, a treatment for acromegaly, has been approved by the UK MHRA, offering a new option for adult patients. Launch expected in late 2025.

Camurus Receives Green Light for Oczyesa® to Treat Acromegaly in the UK #United_Kingdom #Lund #Camurus #Acromegaly #Oczyesa®

FlawLezZ

@absolutelymint.bsky.social

7 months ago

Namn: Camurus💊
Lista: Large Cap
Börsvärde: 40 420 MSEK
Antal ägare: 9 723
Rapport: 2025-07-17 Q2
PE-Tal: 57,6
Omsättningstillväxt Q-Q: 51,8,2% 📷
EBIT-tillväxt Q-Q: 253,5% 📷

#finanstwitter #fintwit #börsdata #pratapengar #aktier #Avanza
@avanza.se @borsdata.bsky.social #Camurus $CAMX

Thiard News@F4F

@newsen.bsky.social

8 months ago

Camurus' Oczyesa® Secures Marketing Approval in the EU for Acromegaly Camurus announces that Oczyesa®, a subcutaneous octreotide depot, has received marketing authorization in the EU for treating acromegaly.

Camurus' Oczyesa® Secures Marketing Approval in the EU for Acromegaly #Sweden #Lund #Camurus #Oczyesa #Acromegaly

Thiard News@F4F

@newsen.bsky.social

8 months ago

Camurus' Oczyesa® Approved in the EU for Acromegaly Treatment Camurus announced the EU approval of Oczyesa®, a subcutaneous octreotide depot for acromegaly treatment, marking a significant advancement in patient care.

Camurus' Oczyesa® Approved in the EU for Acromegaly Treatment #Sweden #Lund #Camurus #Oczyesa #Acromegaly

Thiard News@F4F

@newsen.bsky.social

8 months ago

Camurus' POSITANO Study Reveals Promising Results for CAM2029 in Treating Polycystic Liver Disease Camurus' innovative product CAM2029 shows significant efficacy in treating patients with polycystic liver disease as demonstrated in the recent POSITANO study.

Camurus' POSITANO Study Reveals Promising Results for CAM2029 in Treating Polycystic Liver Disease #Sweden #Lund #Camurus #CAM2029 #Polycystic_Liver_Disease

Thiard News@F4F

@newsen.bsky.social

8 months ago

Camurus' POSITANO Study Reveals Promising Effects of CAM2029 for Patients with Polycystic Liver Disease Camurus has unveiled positive results from its POSITANO study, demonstrating that CAM2029 effectively reduces liver volume growth in patients suffering from polycystic liver disease, with an ongoing follow-up planned.

Camurus' POSITANO Study Reveals Promising Effects of CAM2029 for Patients with Polycystic Liver Disease #USA #Lund #Camurus #CAM2029 #Polycystic_Liver_Disease

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

9 months ago

Eli Lilly and Camurus enter cardiometabolic health partnership worth up to $870m - PMLiVE The deal gives Lilly exclusive global rights to incretin products based on Camurus’ technology

#EliLilly #Camurus #cardiometabolichealth #incretinproducts #FluidCrystal #dualGIPandGLP1receptoragonists #tripleGIP #glucagonreceptoragonists #GLP1receptoragonists #amylinreceptoragonists #obesity #diabetes #RNAitherapeutics #OliXPharmaceuticals #MASH
pmlive.com/pharma_news/...

Thiard News@F4F

@newsen.bsky.social

9 months ago

Camurus and Eli Lilly Join Forces for Innovative Long-Acting Incretin Therapies A new partnership between Camurus and Eli Lilly aims to develop long-acting incretin products for treating cardiometabolic health, enhancing options for patients.

Camurus and Eli Lilly Join Forces for Innovative Long-Acting Incretin Therapies #Sweden #Lund #Eli_Lilly #Camurus #FluidCrystal

Thiard News@F4F

@newsen.bsky.social

9 months ago

Camurus and Eli Lilly Join Forces to Accelerate Incretin Therapies for Chronic Diseases Camurus collaborates with Eli Lilly to develop long-acting incretin therapies for metabolic health, with potential earnings reaching $870 million.

Camurus and Eli Lilly Join Forces to Accelerate Incretin Therapies for Chronic Diseases #Sweden #Lund #Eli_Lilly #Camurus #FluidCrystal

@rookien1.bsky.social

9 months ago

#camurus nästan lite tråkigt att det inte är #novo utan #lilly

FlawLezZ

@absolutelymint.bsky.social

10 months ago

#Camurus 🔥🔥🔥

Lukas Sandelin

@lsandelin.bsky.social

10 months ago

#Camurus Q1-2025

Totala intäkter: 558,3 (390) YoY: 43,2%
EBIT: 238,9 (78,7) YoY: 204%
EBIT-marginal: 42,8% (20,2%)

FoU Kostnaderna har gått från att vara 64,7% av intäkterna helår 2021 till 23,5% i Q1-2025

#Finanstwitter #BorsdataSpotlight

Ola Pihl

@olapihl.bsky.social

10 months ago

#Camurus Nöjd!

ValueCap

@valuecap.bsky.social

10 months ago

I lilla portföljen gick #RaySearch sämst idag med en uppgång på 2,96%. Både #Camurus och #Bonesupport var upp över 5%.
Portföljen har gått från -9% till +9% på under 3 veckor.
#Camurus ser ut att bryta upp över tidigare toppar, kan bli riktigt bra framöver. Någon sett någon nyhet?
#Finanstwitter

Thiard News@F4F

@newsen.bsky.social

10 months ago

European Medicines Agency Praises Oczyesa® for Acromegaly Treatment Advancement The CHMP recommends Oczyesa® for adult acromegaly treatment, enhancing patient care with convenient self-administration and improved outcomes.

European Medicines Agency Praises Oczyesa® for Acromegaly Treatment Advancement #Sweden #Lund #Camurus #Oczyesa #Acromegaly

Thiard News@F4F

@newsen.bsky.social

10 months ago

Camurus Gets Positive EU Recommendation for Oczyesa® to Treat Acromegaly Patients Camurus has received a favorable opinion from the CHMP for its drug Oczyesa® to treat acromegaly, paving the way for broader patient access and innovative treatment options.

Camurus Gets Positive EU Recommendation for Oczyesa® to Treat Acromegaly Patients #Sweden #Lund #Camurus #Oczyesa #CHMP

FlawLezZ

@absolutelymint.bsky.social

10 months ago

ABG rekommendera #Camurus som veckan top pick! Rekommendation köp och riktkurs 750 kr! 🔥
Långsiktigt värde beräknas till 932 kr! 🔥🔥

#fintwit #finanstwitter #pratapengar #aktier $CAMX @abg #ABG

Ola Pihl

@olapihl.bsky.social

1 year ago

Jon Garay Alonso kommer att lämna sin anställning som bolagets Chief Financial Officer (CFO)
#Camurus